Lolly
04-06-2006, 11:41 AM
A Phase II Trial of Letrozole Plus OSI-774 (Tarceva) in Post-Menopausal Women With ER and/or PR-Positive Metastatic Breast Cancer
http://www.clinicaltrials.gov/ct/show/NCT00179296
“In this study a drug called Tarceva (OSI- 774) will be given in combination with the standard treatment of letrozole for advanced metastatic breast cancers which are sensitive to hormonal treatment…
Primary Outcomes: To determine the rate of clinical benefit (CR + PR + SD) in patients with hormone-dependent metastatic breast cancer treated with the combination of the aromatase inhibitor letrozole plus the EGFR/HER2 inhibitor OSI-774 (‘Tarceva’)..."
http://www.clinicaltrials.gov/ct/show/NCT00179296
“In this study a drug called Tarceva (OSI- 774) will be given in combination with the standard treatment of letrozole for advanced metastatic breast cancers which are sensitive to hormonal treatment…
Primary Outcomes: To determine the rate of clinical benefit (CR + PR + SD) in patients with hormone-dependent metastatic breast cancer treated with the combination of the aromatase inhibitor letrozole plus the EGFR/HER2 inhibitor OSI-774 (‘Tarceva’)..."